Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXL104/ceftazidime plus metronidazole versus meropenem for complicated intra-abdominal infection
2008-005604-54Phase 2Completed
- Sponsor
- Novexel
- Start
- Apr 2009
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Intra-abdominal infection (IAI) comparing NXL104/ceftazidime plus metronidazole with Meropenem (2 arms). Primary endpoints: Clinical response at Test of Cure in microbiologically evaluable population and Incidence of adverse experiences. Started Apr 2009; status: completed.
02
Drugs
avibactamceftazidimemetronidazolemeropenem
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2008-005604-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005604-54.